Russian Heart Failure Journal 2010year First angiotensin converting enzyme inhibitor captopril: mechanisms of cardioprotective effects and clinical efficacy


To access this material please log in or register

Register Authorize
2010/

First angiotensin converting enzyme inhibitor captopril: mechanisms of cardioprotective effects and clinical efficacy

Preobragenskiy D. V., Nekrasova N. I., Talyzina I. V., Bugrimova M. A.

Keywords: arterial hypertension, myocardial infarction, captopril, cardioprotective effect, type 2 diabetes mellitus, CHF

DOI: 10.18087/rhfj.2010.3.1345

First ACE inhibitor captopril plays an important role in the treatment of cardiovascular diseases and diabetes mellitus complications. Captopril is one of the most effective drugs with wide range of clinical applications – from hypertensive crisis relief to long-term treatment of patients with hypertension, CHF and diabetes. Captopril is also one of few ACE inhibitors, which are able to prevent heart failure development and improve survival of patients with acute MI.
  1. Opie LH. Angiotensin converting enzyme inhibitors. The advance continues. 3 edition. Authors’ Publishing House, New-York, 1999. – 275.
  2. Brunner HR, Waeber B, Nussberger J. Angiotensin-converting enzyme inhibitors. – In: Messerli F. (ed.). Cardiovascular drug therapy. 2th edition. – Philadelphia, 1996. – pp. 690–711.
  3. Сидоренко Б. А., Преображенский Д. В. Ингибиторы ангиотензин-превращающего фермента. – М.: ЗАО "Информатик", 1999. – 253 с.
  4. Сидоренко Б. А., Преображенский Д. В., Батыралиев Т. А. Ингибиторы АПФ и АТ1‑блокаторы в клинической практике. Часть третья. – Москва, 2004.
  5. Сидоренко Б. А., Преображенский Д. В., Батыралиев Т. А. Ингибиторы ангиотензин превращающего фермента. – М.: Литтерра, 2007. – 352 с
  6. Punzi H. A., Zusman R. M. Captopril. – In: F. Messerli (ed.). Cardiovascular drug therapy. 2th edition. – Philadelphia, 1996. – pp. 726–742.
  7. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension. Arch Intern Med. 1994;154 (5):513–523.
  8. Packer M. Why do kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol. 1987;60 (1):179–184.
  9. Nelson KM, Yeager BF. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Ann Pharmacother. 1996;30 (9):986–993.
  10. Cushman DW, Wang FL, Fung WC et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol. 1989;28 (Suppl 2):115S-130S.
  11. Cushman DW, Wang FL, Fung WC et al. Differentiation of angiotensin converting enzyme (ACE) inhibitors by selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2 (4):294–306.
  12. Pfeffer MA, Braunwald E, Moye LA et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327 (10):669–677.
  13. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342 (8875):821–828.
  14. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333 (25):1670–1676.
  15. de Nigris F, D’Armiento F, Somma P et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol. 2001;81 (2-3):107–115.
  16. Inukai T, Yoshida N, Wakabayashi S et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus. Am J Med Sci. 2005;329 (5):222–227.
  17. Münzel T, Keaney JF Jr. Are ACE inhibitors a «magic bullet» against oxidative stress? Circulation. 2001;104 (13):1571–1574.
  18. Haenni A, Berglund L, Reneland R et al. The alterations in insulin sensitivity during angiotensin-converting enzyme inhibitor treatment are related to changes in the calcium / magnesium balance. Am J Hypertens. 1997;10 (2):145–151.
  19. Barbagallo M, Dominguez LJ, Resnik LM. Protective effects of captopril against ischemic stress. Role of cellular Mg. Hypertension. 1999;34 (4 Pt 2):958–963.
  20. Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328 (13):914–921.
  21. Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Anti­hypertensive Agents. Am J Hypertens. 1995;8 (2):189–192.
  22. Gottdiener JS, Reda DJ, Massie BM et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95 (8):2007–2014.
  23. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353 (9153):611–616.
  24. Pitt B, Segal R, Martinez FA et al; on behalf of the ELITE investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Eldery Study, ELITE). Lancet. 1997;349 (9054):747–752.
  25. Pitt B, Poole-Wilson PA, Segal R et al on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):1582–1587.
  26. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360 (9335) :752–760.
Preobragenskiy D. V., Nekrasova N. I., Talyzina I. V. et al. First angiotensin converting enzyme inhibitor captopril: mechanisms of cardioprotective effects and clinical efficacy. Russian Heart Failure Journal. 2010;11(3):170-176.

To access this material please log in or register

Register Authorize
Ru En